Pioneering
Hybrid DrugsTM
A New Class of Medicine - integrating software with pharmaceutical drugs.
What are Hybrid DrugsTM?
Hy·brid Drugs: (plural noun)
Pharmaceutical Molecules + AI-driven Therapeutic Protocols =
Designed for Better Clinical Outcomes
Hybrid Drugs integrate traditional medication with app-delivered, digital interventions that enhance motor, cognitive, and mental function. Hybrid Drugs can be brought to market pursuant to the existing Drug-SaMD combination pathway, or by leveraging the emerging FDA PDURS framework.
Regulated like medicine, adaptive like software, and reimbursed like pharma, Remepy’s Hybrid Drugs are designed to deliver better outcomes, introducing a new growth model for the industry.
HybridopaTM
Our Hybrid Drug Program for Parkinson’s Disease
Hybridopa, a drug-software combination product in development that pairs immediate release carbidopa levodopa with a digital protocol designed to improve Parkinson's disease treatment.
This Drug-SaMD combination drug will soon enter a phase 3 trial.
Results from our Phase 2 study that met its primary endpoint can be found in Brain Communications and npj Parkinson’s.
Living with Parkinson's, or caring for someone who is?
Join our community to be the first to get research and trial updates..
Rooted in Deep Science
At Remepy, data, behavioral and neuroscience converge. Our digital protocols draw on validated interventions, that are monitored and adapted via AI models, in speech, motor, cognitive, and emotional domains - each designed to modulate key biological mechanisms.
These mechanisms are translated into daily, adaptive protocols delivered through our app and paired with medication to amplify therapeutic outcomes. Learn more
Scientific Publications
Managing Disease at the Intersection of Biology, Behavior & Therapy
In the News
FAQs
Hybrid drugs are therapies that combine traditional medications with digital therapeutics. Remepy is a global leader in hybrid drug development, bringing this new treatment model to patients worldwide.
Remepy Hybrid Drugs integrate pharmaceutical drugs with non-pharmaceutical interventions, each activating different physiological mechanisms, delivering more comprehensive results.
Hybrid drugs, such as those developed by Remepy, represent the future of personalized care by uniting pharmaceuticals and digital health in one therapy.
PDURS creates a new regulatory framework for integrating drugs with software, and leveraging the clinical benfits of the software as part of a drug label. Remepy is partnering with pharma companies, that leverage this framework to integrate therapeutic software with their drugs.